Medicare Advantage & Part D Rate Setting (Advanced Notice & Rate Announcement)

Analysis updated November 9, 2026

Strategic questions for your team

Given that CMS releases the Advance Notice in late January (e.g., 2027 Advance Notice released January 26, 2026) and the final Rate Announcement in early April (e.g., 2027 Announcement released April 6, 2026), do we have an internal governance process that can analyze proposed rate changes, model financial impact scenarios, and submit formal comment letters within the roughly 60-day window between Advance Notice and Announcement — and are our MA plan partners sharing their preliminary capitation impact estimates with us during that window?
How does our organization's payer mix and contract structure with MA plans expose us to the downstream financial effects of year-over-year benchmark rate changes — specifically, do our MA contracts include pass-through provisions, risk corridors, or rate renegotiation triggers tied to CMS benchmark shifts, and have we modeled the revenue impact of a 1–3% swing in county-level benchmarks across our top five MA plan relationships?
In light of CMS's proposed adjustments for anomalous claims data from 2023–2024 (referenced in the 2027 Advance Notice supporting documents), do we have the claims analytics infrastructure to assess how our own facility's coding and billing patterns compare to the national distribution used in risk score calibration — and are we at risk of revenue compression if CMS normalizes away codes that reflect genuine patient complexity in our population?
For health systems operating in Maryland, have we fully evaluated the financial and operational implications of the proposed Maryland IME/DGME carveout (raised in the 2025 Advance Notice) and the proposed Maryland KAC carveout (raised in the 2026 Advance Notice), including how these carve-outs affect our MA payment rates, our cost reimbursement under the Maryland All-Payer Model, and whether advocacy through the comment period is warranted to protect our position?
Given CMS's inclusion of proposed rural emergency hospital facility payment adjustments in the 2027 Advance Notice supporting documents, do our rural or critical access hospital facilities qualify for rural emergency hospital designation, and have we modeled whether conversion or qualification would improve our MA payment rates and financial sustainability relative to current inpatient volume thresholds?
Do our MA plan contracting teams and ACO finance staff monitor the MAC (Medicare Administrative Contractor) jurisdiction updates published alongside the Advance Notice — such as the MAC Jurisdiction June 2024 document released with the 2026 Advance Notice — and do we understand how jurisdiction-level fee schedule and benchmark changes affect site-of-care payment differentials for procedures performed across our multisite system?
Have we built a multi-year rate trend model using the historical Advance Notice and Announcement cadence (dating back to at least 2020) to identify patterns in the gap between proposed and final rates, and are we using that analysis to stress-test our MA revenue projections in our three-year operating budget against scenarios where final rates land below the Advance Notice proposal?
For ACO leaders participating in or considering MSSP or REACH models with significant MA-aligned attribution, how are we tracking the interplay between MA benchmark rate setting and our prospective vs. retrospective attribution methodologies — and do rate compression scenarios in key counties threaten the financial viability of our shared savings strategy by reducing the baseline against which our savings are measured?
Are our physician group administrators and coding compliance teams prepared for potential HCC model recalibration announced in each Rate Year cycle, and do we have a prospective risk adjustment program that ensures accurate, complete, and defensible capture of chronic condition hierarchies — particularly given CMS's ongoing scrutiny of MA risk score growth reflected in its anomalous claims adjustment proposals in the 2027 Advance Notice?
Given the annual regulatory calendar — with Early Previews historically released in November–December, Advance Notices in January–February, and final Announcements in late March–early April — have we aligned our MA contract negotiation timelines with this cycle so that multi-year rate agreements with MA plans are renegotiated after final Rate Announcements rather than locked in during the uncertainty period between Advance Notice and Announcement?
Given that the final 2027 MA payment rate increase was set at 2.48% — a figure that insurers have signaled is insufficient to maintain current supplemental benefit offerings — have we assessed the downstream risk to our MA-aligned revenue streams from anticipated benefit reductions (e.g., dental, vision, OTC, gym perks, transportation) that our patient population currently relies on, and have we modeled how benefit curtailments could affect care-seeking behavior, volume, and payer mix at our facilities?
In light of major insurers including Humana and UnitedHealthcare discontinuing MA plans affecting nearly 1 million beneficiaries for 2027, and MA prescription drug plan options declining for the third consecutive year, have we assessed how plan exits or consolidations in our key markets will affect our MA-contracted volumes — and do we have contingency contracting strategies if beneficiaries in our service area lose access to their current plan and must re-enroll in surviving options with different network or payment terms?
Given that 2027 CMS Star Rating averages dropped for MA plans — which directly affects quality bonus payments and benchmark rates — have we evaluated how the Star Rating performance of our key MA plan partners affects the benchmark rates under which we are paid, and are we engaging those partners on quality improvement initiatives that could restore higher Star Ratings and associated revenue in future rate years?
Given that insurer stock prices rallied on the 2027 MA rate announcement as a positive surprise while health plans simultaneously clash with CMS over the adequacy of the 2.48% increase, do our MA contract renegotiation strategies account for the divergence between insurers' public advocacy positions and their actual financial posture — and are we using independent rate modeling rather than relying solely on plan-provided impact estimates when setting our negotiating parameters?
Given the simultaneous market signals of declining MA plan options, major insurer pullbacks affecting nearly 1 million beneficiaries, and premium reductions for 2027, have we modeled the volume and payer-mix implications of large-scale MA-to-traditional-Medicare transitions in our service area — and do our revenue cycle and care management teams have protocols to support beneficiaries navigating involuntary plan changes?

Traps and concerns

Risk Model Recalibration Revenue Shock
CMS recalibrates the HCC (Hierarchical Condition Category) risk adjustment model periodically, and each recalibration can produce significant revenue swings for MA plans before the final Announcement locks in rates. The multi-year phase-in of the updated risk model (v28) — introduced across the 2024, 2025, and 2026 rate years — reduces the weight of many condition categories relative to prior models. Plans that coded aggressively to legacy HCC weights face a structural revenue cliff as the phase-in completes. For 2026, CMS finalized the third and final year of the v28 transition, meaning plans no longer have the partial-year blending buffer. Organizations that built their actuarial bids around blend-period assumptions and failed to update PMPM projections to a fully v28-weighted portfolio are exposed to margin compression that cannot be recovered mid-contract year. The financial impact is non-trivial: even a 1–2% shift in risk scores across a large enrollment base translates to tens of millions of dollars in capitation revenue annually.
Advance Notice‑to‑Announcement Delta Mismanagement
The annual rate-setting cycle runs on a compressed, high-stakes timeline: the Advance Notice is released in late January (e.g., 2027 Advance Notice released January 26, 2026; 2026 Advance Notice released January 10, 2025), followed by a comment period, with the final Announcement published in early April (e.g., 2027 Announcement released April 6, 2026; 2026 Announcement released April 7, 2025). Plans must submit bids to CMS by early June for the following contract year. This creates a roughly 10-week window between final Announcement and bid submission. Plans that lock actuarial assumptions or premium/benefit structures before the Announcement is finalized — or that fail to fully model the delta between Advance Notice proposals and final Announcement changes — can file bids that are misaligned with actual benchmark rates and county-level payment amounts. The Maryland KAC carveout impact document accompanying the 2026 Advance Notice and the Maryland IME/DGME carveout analysis in the 2025 Advance Notice illustrate how geographically specific policy changes can materially alter county benchmarks in ways that a national or regional actuarial model may not capture until after bids are due. For 2027, the Trump administration finalized a 2.48% effective payment rate increase, representing approximately $13 billion in additional payments to insurers — a figure that diverged from insurer expectations and triggered public disagreement between CMS and major plans about the adequacy of the final rate. Plans that modeled the final Announcement based on industry advocacy positions rather than the actual April finalization were exposed to bid misalignment.
Anomalous Claims Adjustment Retroactive Exposure
The 2027 Advance Notice introduced a proposed adjustment for anomalous claims from 2023–2024, signaling CMS's willingness to make retroactive corrections to the data inputs used for rate-setting when it identifies aberrant utilization patterns. This is a distinct payment/reconciliation risk: even after rates are finalized in the April Announcement, CMS may apply prospective adjustments in subsequent rate years to correct for identified anomalies in the fee-for-service (FFS) cost data underlying the benchmarks. Plans that have already locked multi-year financial projections, premium structures, or value-based care contracts with downstream providers based on the pre-adjustment benchmark cannot unwind those commitments. The operational hazard is compounded for plans in markets with high concentrations of the affected claim types, where the benchmark reduction could be materially above the national average adjustment. Plans should stress-test their bid models against a range of anomalous-claims adjustment scenarios before finalizing actuarial assumptions.
Rural Emergency Hospital Payment Rate Uncertainty
The 2027 Advance Notice included a proposed rural emergency hospital (REH) facility payment document covering 2023–2024, reflecting CMS's ongoing effort to integrate REH facility type payments into MA rate-setting methodology. For MA plans operating in rural markets, uncertainty about how REH facility costs are treated in the FFS normalization data — and whether REH payments are carved in or out of county benchmarks — creates a direct pricing risk. If REH costs are ultimately excluded from the benchmark calculation but MA plans are required to cover REH services, the effective cost obligation exceeds the payment basis. Conversely, plans that assumed REH coverage obligations would be benchmark-supported and priced accordingly may face network adequacy enforcement actions if they subsequently narrow REH participation to manage costs. Rural-focused plans and those serving counties with newly designated REH facilities face the greatest exposure.
Star Ratings Cliff and Quality Bonus Payment Dependency
MA plans rated 4 stars or higher receive Quality Bonus Payments (QBPs) that can materially increase their effective benchmark — in some cases enabling plans to offer $0-premium, low-cost-sharing products that are central to their competitive positioning and enrollment growth strategy. The rate-setting cycle and Star Ratings cycle are interlinked but not synchronized: Star Ratings are released in the fall preceding the Advance Notice, but their financial impact flows through the April Announcement. A plan that drops from 4 to 3.5 stars loses QBP eligibility for the entire following contract year, eliminating a revenue stream that may have been factored into bid assumptions, provider contract structures, and marketing commitments already in the market. KFF confirmed that average Star Ratings across MA plans declined for 2027, compounding the margin pressure already present from the 2.48% rate increase. Given that CMS has adjusted Star Ratings methodology in recent years — including changes to the Health Equity Index and weighting of patient experience measures — plans face a regulatory compliance risk in ensuring data submissions and HEDIS measure performance are accurately captured and that any disputes are resolved before the annual deadline.
County Benchmark Volatility from FFS Normalization Changes
County-level MA benchmarks are derived from FFS expenditure data normalized for underlying cost differences. Changes to the normalization methodology — including updates to the geographic adjustment factors, changes in which FFS claims are included or excluded, or shifts in the applicable percentages (published as a separate document accompanying each Advance Notice, e.g., 'Applicable Percentages for CY 2027,' 'Applicable Percentages for CY 2026,' 'Applicable Percentages for CY 2025') — can produce significant county-by-county benchmark shifts that are not visible until the Advance Notice is released in January. Plans with high enrollment concentration in a small number of counties are especially vulnerable: a benchmark reduction of even 2–3% in a high-enrollment county directly reduces the capitation revenue available to fund benefits and administration. Health systems and provider-sponsored organizations that entered the MA market based on projected county benchmarks face particular risk, as their cost structures are often less flexible than national payers and their geographic diversification is limited.
Part D Direct Subsidy and Reinsurance Reconciliation Lag
Part D payment parameters — including the base beneficiary premium, the direct subsidy, low-income cost-sharing subsidies, and the reinsurance payment amounts — are finalized in the April Announcement and subject to retrospective reconciliation based on actual drug costs. With the Inflation Reduction Act's $2,000 annual out-of-pocket cap and the restructured catastrophic phase taking effect in 2025, the reinsurance reconciliation dynamic has shifted materially: CMS now bears a larger share of catastrophic costs, but the reconciliation timeline means Part D sponsors carry interim cash flow exposure for months before settlement. The operational and technology risk is that plan systems must accurately track beneficiary cost accumulation across the new benefit design in real time — both for member cost-sharing and for correct application of the manufacturer discount program and government reinsurance — and errors in accumulator logic can trigger significant reconciliation liabilities or overpayment demands. Plans that under-invested in benefit administration system upgrades ahead of the 2025 plan year face the highest exposure to reconciliation errors and potential CMS audit findings.
Plan Culling and Market Stability Risk from Margin Pressure
CMS data released in late September 2026 shows insurers continuing to reduce the number of MA plan offerings for 2027, a trend CMS publicly characterized as reflecting market 'stability' but which industry observers and trade press characterized as a direct response to sustained margin pressure. KFF confirmed that Medicare Advantage prescription drug plan options declined for the third consecutive year heading into 2027. Humana and UnitedHealthcare are discontinuing MA plans affecting nearly 1 million people for 2027, illustrating that culling has moved beyond incremental benefit trimming to large-scale plan exits. When plans exit counties or consolidate offerings, beneficiaries face disrupted coverage, limited plan choice, and potential loss of supplemental benefits — triggering regulatory scrutiny and member retention risk. The operational trap for remaining plans is compounded: as competitors exit, enrollment may shift rapidly and unpredictably into remaining plans, creating adverse selection dynamics and utilization volatility that was not embedded in the original bid assumptions. Plans that modeled enrollment projections based on a stable competitive landscape — and priced benefits or built provider networks accordingly — face the risk that unexpected enrollment growth in disrupted markets strains network capacity and increases MLR above bid targets. Some insurers have responded by selectively adding benefits in targeted geographies (e.g., Independence Blue Cross expanding 2027 MA options with a new Keystone 65 Assured HMO) even while national players pull back elsewhere, creating a bifurcated competitive dynamic that can distort enrollment projections for plans that do not model competitor behavior at the county level.
Supplemental Benefit Retrenchment and Member Retention Risk
MA plans are trimming dental, vision, gym, and other supplemental benefits for 2027 in direct response to margin compression from inadequate rate increases and declining Star Ratings. Because supplemental benefits are a primary enrollment and retention driver — and are marketed aggressively during the Annual Enrollment Period — benefit reductions create a dual risk: members who enrolled specifically for those benefits may disenroll or switch plans, generating adverse selection and enrollment volatility mid-contract year; and plans that communicated benefit packages publicly before finalizing bid economics may face member relations or regulatory scrutiny if announced benefits are subsequently reduced. Plans that benchmarked their supplemental benefit packages against competitor offerings without stress-testing the revenue adequacy of those packages under a low-rate-increase scenario are particularly exposed. The retrenchment dynamic also creates a reputational and regulatory risk at the program level, as CMS and Congress may respond to visible benefit erosion with policy interventions that alter the rate-setting or bid framework mid-cycle.
Premium Projection Mismatch from CMS Benchmark vs. Plan Cost Divergence
CMS projected a 16.5% drop in average 2027 MA premiums — a figure driven by benchmark changes and plan benefit restructuring in the wake of margin pressure — while simultaneously finalizing only a 2.48% effective payment rate increase representing approximately $13 billion in additional payments. This divergence between headline premium metrics and underlying payment adequacy creates a strategic trap: plans that interpret falling average premiums as a signal of improved market competitiveness may underprice benefits or overcommit to supplemental benefit packages that are not supportable given their actual capitation revenue. The headline premium decline reflects benefit reductions and plan culling across the market, not genuine cost efficiency gains. Plans that benchmark their pricing strategy against the market average premium without decomposing the drivers of that average — competitor exits, benefit stripping, enrollment mix shifts — are exposed to adverse selection and margin compression in the contract year.